Arthritis Care & Research最新文献

{"title":"Temporal Trends and Demographic Insights Into Mortality From Systemic Lupus Erythematosus, 1999-2020.","authors":"Ansaam Daoud, Loai Dweik, Omer Pamuk","doi":"10.1002/acr.25509","DOIUrl":"10.1002/acr.25509","url":null,"abstract":"<p><strong>Objective: </strong>Previous studies showed a decline in systemic lupus erythematosus (SLE) mortality rates from 1968 to 2013, yet mortality rates remained high relative to non-SLE mortality rates, with notable disparities. We aimed to delineate demographic characteristics associated with SLE deaths and map out the national and geographic trends of the last two decades.</p><p><strong>Methods: </strong>We analyzed SLE deaths data from 1999 to 2020 using the Centers for Disease Control and Prevention's Wide-Ranging Online Data for Epidemiologic Research Multiple Cause of Death database. Age-adjusted mortality rates (AAMRs) were computed based on sex, race and ethnicity, and state. Trends over the study period were evaluated using a simple linear regression model.</p><p><strong>Results: </strong>From 1999 to 2020, we identified 27,213 deaths with SLE as the underlying cause in the United States. Female participants experienced a higher AAMR (6.21 per million, 95% confidence interval [95% CI] 6.13-6.29) than male participants (1.20 per million, 95% CI 1.16-1.24). African American participants had the highest AAMR (10.7 per million, 95% CI 10.48-10.92), particularly among female participants (17.68 per million, 95% CI 17.29-18.06). Linear regression analysis found a significant decline in the SLE AAMR from 1999 to 2020 (R² = 0.902), with decreases noticed across all demographic groups. The SLE AAMR to the non-SLE AAMR ratio showed a sustained decline from 2005 to 2020 (R² = 0.8552). Analysis of the geographic distribution of SLE AAMR in the United States reveals a pronounced concentration in Southern states.</p><p><strong>Conclusion: </strong>Since 1999, SLE-related mortality rates have consistently declined across various demographic groups, though rates remain disproportionately high in African American participants, particularly among African American female participants and in Southern states.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143397922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lupus Flares: More Common in Dialysis Patients Than in Post-Kidney Transplant Recipients: A Systematic Review and Meta-Analysis.","authors":"Ansaam Daoud, Loai Dweik, Niraj Desai, Sarfaraz A Hasni, Omer N Pamuk","doi":"10.1002/acr.25507","DOIUrl":"10.1002/acr.25507","url":null,"abstract":"<p><strong>Objective: </strong>In this study, we performed a systematic literature review and meta-analysis to assess the frequency of systemic lupus erythematosus (SLE) flares in patients with end-stage renal disease (ESRD) and patients undergoing renal replacement therapy (RRT), hemodialysis (HD), peritoneal dialysis (PD), and kidney transplant (KT).</p><p><strong>Methods: </strong>Literature from 1973 to 2023 was searched for studies on the frequency of lupus flares after RRT. Data were extracted for ESRD and each RRT modality. Forest plots and random effect models were used to evaluate the odds ratios (95% confidence interval [CI]) of SLE flares after ESRD or RRT, and study heterogeneity was assessed using I² statistics.</p><p><strong>Results: </strong>A total of 57 studies fulfilled the study entry criteria. A total of 29 studies evaluated extrarenal SLE flares after HD/PD, and five studies evaluated extrarenal SLE flares after KT. The frequency of extrarenal SLE flares was compared between HD and PD in seven studies and between HD/PD and KT in four studies. The recurrence of lupus nephritis (LN) was analyzed in 29 studies. Overall, 35.9% of patients with ESRD had at least one extrarenal flare after RRT. The frequency of extrarenal SLE flare was similar in PD and HD (oods ratio [OR] 1.05, 95% CI 0.57-1.94). Extrarenal flare risk was significantly higher in the PD/HD group compared with that of the KT group (OR 4.36, 95% CI 1.66-11.47; P = 0.0028). The recurrence of LN after KT was 3.39%.</p><p><strong>Conclusion: </strong>Extrarenal lupus flares can still occur in more than one-third of patients with ESRD receiving RRT. Dialysis patients have a higher flare risk than those after KT, with comparable flare risk among patients receiving HD and PD.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143397916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Pharmacologic and Nonpharmacologic Interventions for the Management of Sleep Problems in People With Fibromyalgia: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.","authors":"Jemma Hudson, Mari Imamura, Clare Robertson, Daniel Whibley, Lorna Aucott, Katie Gillies, Paul Manson, Debra Dulake, Abhishek Abhishek, Nicole K Y Tang, Gary J Macfarlane, Miriam Brazzelli","doi":"10.1002/acr.25505","DOIUrl":"10.1002/acr.25505","url":null,"abstract":"<p><strong>Objective: </strong>Fibromyalgia is a chronic condition characterized by widespread musculoskeletal pain and fatigue. Almost everyone with fibromyalgia has sleep problems. We aimed to evaluate the effectiveness and safety of current interventions for the management of fibromyalgia-related sleep problems.</p><p><strong>Methods: </strong>Major electronic databases were searched in November 2021. We focused on randomized controlled trials assessing pharmacologic and/or nonpharmacologic interventions in adults and children and identified 168 studies for inclusion. We assessed the methodologic quality of included studies using the Cochrane Risk-of-Bias tool. Our primary outcome of interest was sleep quality assessed using validated patient-reported outcome measures.</p><p><strong>Results: </strong>Results from primary studies were analyzed using network meta-analyses (NMA). The NMA for sleep quality included 65 studies evaluating 35 treatment categories (8,247 participants). Most studies were at high overall risk of bias. Compared with placebo or sham treatments, there was some evidence that exercise (specifically land-based aerobic exercise training in combination with flexibility training [standardized mean difference (SMD) -4.69, 95% credible interval (Crl) -8.14 to -1.28] and aquatic-based aerobic exercise training [SMD -2.63, 95% Crl -4.74 to -0.58]) may improve sleep. There was also a suggestion that land-based strengthening exercise, psychological and behavioral therapy with a focus on sleep, electrotherapy, weight loss, dental splints, antipsychotics, and tricyclics may have a modest effect on sleep.</p><p><strong>Conclusion: </strong>There is a low level of certainty surrounding the effectiveness of interventions for the management of sleep problems in people with fibromyalgia, but some forms of exercise training appear more likely to provide an improvement in sleep quality.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143389694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Benefits of Early Versus Late Initiation of Intravenous Immunoglobulin in the Treatment of Patients With Anti–3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy","authors":"","doi":"10.1002/acr.25496","DOIUrl":"10.1002/acr.25496","url":null,"abstract":"<p>Sharf K, Do T, Ghetie D, Choi D, Chahin N. Benefits of Early Versus Late Initiation of Intravenous Immunoglobulin in the Treatment of Patients With Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy. Arthritis Care Res (Hoboken). 2024 Nov;76(11):1584-1592. doi: 10.1002/acr.25406.</p><p>In Table 2, all values for serum CK should be reported in units per liter (U/L), not L/L as mistakenly published. See below for the corrected Table 2.</p><p>Thank you for correcting this,</p><p>Kyle Sharf, DO</p><p>Nizar Chahin, MD</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":"77 3","pages":"419"},"PeriodicalIF":3.7,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acr.25496","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Geographic Clustering of Systemic Sclerosis in Areas of Environmental Pollution.","authors":"Noelle N Kosarek, Megan E Romano, Erika L Moen, Robert W Simms, Ashleigh Erickson, Dinesh Khanna, Patricia A Pioli, Michael L Whitfield","doi":"10.1002/acr.25504","DOIUrl":"10.1002/acr.25504","url":null,"abstract":"<p><strong>Objective: </strong>Systemic sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and other organs. SSc is thought to arise in genetically predisposed individuals with occupational triggers, although further environmental etiologies still need to be identified. Limited research exists detailing which environmental factors lead to the downstream inflammatory and fibrotic symptoms experienced by patients with SSc across the United States. This study describes a retrospective cohort of 179,188 individuals with an SSc or SSc-related diagnosis code enrolled in the Medicare beneficiary program between the years 2014 and 2018.</p><p><strong>Methods: </strong>The incidence of SSc and SSc-related diagnosis codes in all US zip codes with beneficiary counts greater than 11 was calculated. We conducted global and local Moran's Index (Moran's I) as well as a hot spot analysis with the Getis Ord Gi statistic to determine whether SSc and SSc-related diagnosis codes exhibited clustered or dispersed patterns across the United States. We identified clusters of SSc and SSc-related diagnosis code with high incidences in or around Superfund sites, which are federally identified areas of environmental contamination.</p><p><strong>Results: </strong>SSc exhibited clustered patterns in two analyzed cohorts based on global Moran's I statistics of 0.588 and 0.521. Results of local Moran's I indicated clusters of disease in Mississippi, New York, Wisconsin, and Michigan, among others. Some zip codes with high disease incidences were home to at least one Superfund site.</p><p><strong>Conclusion: </strong>SSc exhibits nonrandom, clustered distributions in a US Medicare beneficiary cohort composed of 179,188 individuals from 2014 to 2018.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pregnancy Outcomes of Targeted Synthetic Disease-Modifying Antirheumatic Drugs Among Patients With Autoimmune Diseases: A Scoping Review.","authors":"Vienna Cheng, Neda Amiri, Vicki Cheng, Ursula Ellis, Jacquelyn J Cragg, Mark Harrison, Laurie Proulx, Mary A De Vera","doi":"10.1002/acr.25502","DOIUrl":"10.1002/acr.25502","url":null,"abstract":"<p><strong>Objective: </strong>Targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) have expanded the management of autoimmune diseases, including rheumatic diseases. As the use of these drugs grows, it is important to understand their effects on pregnancy. We conducted a scoping review to synthesize the current evidence on the impacts of tsDMARDs on pregnancy outcomes.</p><p><strong>Methods: </strong>We searched the Embase, MEDLINE, and CENTRAL databases in November 2023. We included studies that examined tsDMARD exposure for chronic autoimmune disease(s), particularly in mothers during pregnancy, fathers before conception, and/or fetuses/neonates in utero. We extracted data on sample size, study design, tsDMARD exposure (dose and duration), and reproductive health outcomes.</p><p><strong>Results: </strong>Of 6,712 studies screened, eight were included, namely nine case reports, one case series, four cross-sectional studies, and one cohort study among patients with ulcerative colitis, rheumatoid arthritis, and psoriasis. Sample sizes ranged from 1 to 116 pregnancies or offspring, with six studies on tofacitinib, one on baricitinib, one on upadacitinib, and no studies on apremilast. Overall, 19 fetal/neonatal outcomes, six fetal/neonatal-maternal outcomes, and three maternal outcomes were extracted. The most frequently reported fetal/neonatal outcomes were congenital anomaly (n = 4), preterm birth (n = 4), and the fetal/neonatal-maternal outcome of spontaneous abortion (n = 4). Only one study reported on the maternal outcome of delivery via Cesarean section.</p><p><strong>Conclusion: </strong>Our scoping review of evidence to date on the perinatal use of tsDMARDs reveal small sample sizes and a limited number of studies, all largely descriptive in nature. Findings highlight evidence gaps that preclude providers and patients from making informed decisions when considering the perinatal use of tsDMARDs.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Mortality in Antiphospholipid Antibody-Positive Patients: Prospective Results From Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Clinical Database and Repository.","authors":"Yasaman Ahmadzadeh, Larry S Magder, Danieli Castro Oliveira de Andrade, Diana Paredes-Ruiz, Maria G Tektonidou, Vittorio Pengo, Savino Sciascia, Laura Andreoli, Flávio Signorelli, Paul R Fortin, Maria Efthymiou, H Michael Belmont, Giuseppe Barilaro, Ann E Clarke, Tatsuya Atsumi, Chary López-Pedrera, Jason S Knight, D Ware Branch, Rohan Willis, Nina Kello, Zhuoli Zhang, Esther Rodriguez Almaraz, Bahar Artim-Esen, Jose Pardos-Gea, Guillermo Pons-Estel, Giulia Pazzola, Hui Shi, Alí Duarte-García, Jonathan Thaler, Megan R W Barber, Leslie Skeith, Massimo Radin, Pier Luigi Meroni, Robert Roubey, Maria Laura Bertolaccini, Hannah Cohen, Michelle Petri, Doruk Erkan","doi":"10.1002/acr.25503","DOIUrl":"10.1002/acr.25503","url":null,"abstract":"<p><strong>Objective: </strong>The objective was to determine the mortality rate as well as the causes and predictors of death in antiphospholipid antibody (aPL)-positive patients with and without antiphospholipid syndrome (APS) classification.</p><p><strong>Methods: </strong>The inclusion criterion for the multicenter international Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) registry is positive aPLs according to the Revised Sapporo Classification Criteria tested within one year before enrollment. Patients are observed every 12 ± 3 months with clinical data and blood collection. For this prospective analysis, we first analyzed the causes of death for patients reported as \"deceased.\" Secondly, we analyzed risk factors for death using the adjusted Cox proportional hazards model and calculated survival probability using the Kaplan-Meier model based on different age groups.</p><p><strong>Results: </strong>Of 967 patients, 43 (5%) were deceased after a median follow-up of 5.3 years. Based on the univariate analysis, deceased patients, compared to living patients, were more likely to be older and have a history of arterial thrombosis, catastrophic APS, concomitant systemic autoimmune diseases (SAIDs), and baseline cardiovascular disease (CVD) risk factors. Based on the Cox proportional hazards model adjusted for age and for each of the strongest predictors of death, arterial thrombosis (hazard ratio [HR] 2.94, 95% confidence interval [CI] 1.50-5.76), concomitant SAIDs (HR 2.97, 95% 1.56-5.63), and baseline any CVD risk factor (HR 2.43, 95% CI 1.05-5.71) were significantly associated with mortality.</p><p><strong>Conclusion: </strong>In our cohort of persistently aPL-positive patients, the mortality rate was 5% after a median follow-up of five years and was highest for patients >60 years old at registry entry. History of arterial thrombosis, concomitant SAIDs, and baseline any CVD risk factor independently predicted future death.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143078475","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Priority Musculoskeletal Health Research Questions for People With Generalized Joint Hypermobility: An International Delphi Study.","authors":"Sara Habibian, Verity Pacey, Cliffton Chan, Alan J Hakim, Cylie M Williams","doi":"10.1002/acr.25501","DOIUrl":"10.1002/acr.25501","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to identify the top 10 international research priorities for musculoskeletal health of people with generalized joint hypermobility.</p><p><strong>Methods: </strong>A three-round Delphi method using an online survey was implemented. Three participant stakeholder groups were eligible for inclusion: (1) people with lived experience of joint hypermobility or their carers, (2) health care professionals, and (3) researchers with experience working with individuals with hypermobility. Participants provided up to three priority research questions in round 1. In round 2, participants prioritized 10 research questions from the unique questions proposed in round 1. In round 3, participants were presented with the top 10 questions from the overall cohort and for their stakeholder group(s) and asked to rank these in order of importance.</p><p><strong>Results: </strong>Round 1 commenced with 396 participants who provided 958 individual questions, which reduced to 210 unique questions following data cleaning. There were 257 participants (65% of 396) in round 2, and 249 participants (63% of 396, lived experience n = 230, health care professionals n = 73, and researchers n = 21) in round 3. The overall top-ranked question was, \"How can we prevent disability, pain, and poor quality of life associated with the musculoskeletal comorbidities of symptomatic generalized joint hypermobility?\" Specific stakeholder group priority research questions varied. People with lived experience prioritized treatment questions, whereas health care professionals and researchers prioritized service-impact and utilization research questions.</p><p><strong>Conclusion: </strong>Priority research questions relating to musculoskeletal health of people with generalized joint hypermobility have been internationally identified. These questions provide a future focus for meaningful and necessary research in this field.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physician Views and Attitudes Regarding Tobacco-Cessation Strategies for Patients with Rheumatoid Arthritis.","authors":"Maria A Lopez-Olivo, Johncy J Kachira, Sheneze Madramootoo, Kaleb Michaud, Rebecca Schumacher, Paul Cinciripini, Maria E Suarez-Almazor","doi":"10.1002/acr.25500","DOIUrl":"10.1002/acr.25500","url":null,"abstract":"<p><strong>Objective: </strong>In this study, we explored physicians' level of experience with patients with rheumatoid arthritis (RA) who used tobacco, their views on the effects of tobacco use on the efficacy of RA treatments, and their experiences and attitudes with respect to tobacco-cessation programs.</p><p><strong>Methods: </strong>We conducted qualitative, semistructured interviews of 20 physicians (10 primary care physicians [PCPs] and 10 rheumatologists).</p><p><strong>Results: </strong>The physicians had been in clinical practice for a mean of 9.9 years. Research themes included (1) risk perception of smoking, (2) cessation aids used, (3) preferences to deliver cessation programs, and (4) barriers and facilitators for tobacco cessation. For the first theme, many PCPs did not perceive smoking as influencing RA disease activity. For the second theme, most physicians supported the use of nicotine-replacement therapy and agreed that cessation-drug therapy (eg, varenicline, bupropion) worked better than nicotine-replacement therapy or other cessation strategies, especially in patients with failed cessation attempts. For the third theme, some physicians recommended that patients join the Quitline cessation program and enroll in peer support communities; others found educational programs informing patients about the benefits of quitting and tailored with messages according to patients' specific clinical characteristics to be useful. For the fourth theme, PCPs and rheumatologists reported similar barriers to offering smoking-cessation programs (eg, lack of time, training in tobacco cessation, and financial motivation).</p><p><strong>Conclusion: </strong>Physicians agreed with the need for tailored, multifaceted interventions to support tobacco cessation in patients with RA. However, many perceived major barriers to helping their patients quit, some of which could be overcome by training.</p>","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gout flare prophylaxis trials: comment on the article by Maher et al.","authors":"Naomi Schlesinger, Jamie Dwyer, Jeffrey Carson, Luigi Brunetti","doi":"10.1002/acr.25499","DOIUrl":"10.1002/acr.25499","url":null,"abstract":"","PeriodicalId":8406,"journal":{"name":"Arthritis Care & Research","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}